Elixxir Life Science
Elixxir Life Science is a biotechnology company pursuing therapies to extend human healthspan by targeting the aging process itself. The company's initial focus is developing LINE-1 inhibitors to treat Alzheimer's disease, a leading age-related condition. By addressing this fundamental mechanism of aging, Elixxir aims to slow disease progression and promote longer, healthier lives.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Aging is the primary risk factor for numerous debilitating diseases, including Alzheimer's disease, yet current treatments focus on managing symptoms rather than addressing the underlying biological mechanisms. There is a critical need for therapies that target the fundamental processes of aging to extend healthspan and improve quality of life for the growing elderly population.
Solution
Elixxir Life Science is developing therapies designed to treat age-related diseases by targeting the aging process itself. The company's first therapeutic approach uses LINE-1 inhibitors, which are designed to suppress retrotransposon activity—a key driver of cellular aging and neurodegeneration. By inhibiting these genetic elements, Elixxir aims to slow or halt the progression of Alzheimer's disease and potentially other age-related conditions. The ultimate goal is to increase healthspan, allowing people to live younger and longer by addressing the root causes of aging rather than just its symptoms.
Target Audience
Primary stakeholders include pharmaceutical research partners, clinical researchers specializing in aging and neurodegeneration, and ultimately patients and healthcare providers seeking disease-modifying treatments for Alzheimer's disease and other age-related conditions.
Features
- LINE-1 inhibitor platform targeting retrotransposon-mediated genomic instability as a driver of aging
- Therapeutic focus on Alzheimer's disease as a first clinical indication
- Mechanism designed to address fundamental aging biology rather than symptomatic relief
- Research program aimed at expanding applications to other age-related conditions through the same biological pathway